Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
bicarbonate · 1 trial · 2 indications
The change from Baseline in median pH was calculated as: median pH on Day 7 minus median pH at Baseline. PH measures how acidic or basic a substance is. The pH scale ranges from 0 to 14. A pH of 7 is neutral. A pH less than 7 is acidic. A pH greater than 7 is basic.
| Arm | Type | Description |
|---|---|---|
| Single Dose Zegerid for 1 or 7 days | EXPERIMENTAL | Omeprazole 20 mg/Sodium Bicarbonate 1680 mg Powder for Oral Suspension |
| Single Dose Prilosec 1 or 7 days | ACTIVE_COMPARATOR | Omeprazole magnesium 20 mg over-the-counter (OTC) Tablet |
| Sodium Bicarbonate | ACTIVE_COMPARATOR | Sodium Bicarbonate 1680 mg Oral Suspension |
| Name | Type | Description |
|---|---|---|
| Omeprazole/sodium bicarbonate | DRUG | Omeprazole/sodium bicarbonate. Single dose per day for either 1 or 7 days. |
| omeprazole magnesium | DRUG | Omeprazole 20 mg tablet. Single dose per day for either 1 or 7 days. |
| sodium bicarbonate | DRUG | Sodium bicarbonate. Single dose. |
Inclusion Criteria: * Normal subjects who are 18-65 years of age. * Non-childbearing potential females or those using birth control. Exclusion Criteria: * History of hypersensitivity, allergy or intolerance to omeprazole or other proton pump inhibitors * History of significant gastrointestinal di...
Top 20 of 45 competitors
Bicarbonate is an investigational small molecule being developed for gastric acid conditions. It is currently in Phase 3 clinical development. The drug is being studied for its effects on gastric acid, with a completed Phase 3 trial involving 60 participants.
Bicarbonate is being developed by Bausch + Lomb Corporation, which trades under the ticker BLCO. The company is conducting clinical research on this investigational drug for gastric acid conditions.
Bicarbonate is in Phase 3 clinical development. It has completed one Phase 3 trial, which was an active-controlled, randomized study. The drug is still investigational and has not been approved by regulatory authorities.
Bicarbonate has one completed clinical trial registered as NCT00674115. This Phase 3 study, titled "A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (CL2007-17)(P07813)", enrolled 60 participants and evaluated gastric acid conditions in healthy volunteers.
Bicarbonate was studied in a clinical trial comparing it to Zegerid and Prilosec OTC. However, the drug itself is a separate investigational compound. The trial was active-controlled, meaning it compared bicarbonate against these other treatments for gastric acid.